Top

Clinical and Translational Oncology

Published in:

01-09-2014 | Research Article

Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis

Authors: D. Wan, W. Gu, G. Xu, C. Shen, D. Ding, S. Shen, S. Wang, X. Gong, S. He, Q. Zhi

Published in: Clinical and Translational Oncology | Issue 9/2014

Abstract

Purpose

Emerging evidence has shown that single nucleotide polymorphisms occurred in microRNAs may contribute to the development of colorectal cancer (CRC). rs2910164 in miR-146a and rs11614913 in miR-196a2 are suggested to be associated with the susceptibility to CRC, but individually published studies revealed inconclusive results. To systematically summarize the possible correlationship between these polymorphisms and CRC risk, we performed this meta-analysis.

Methods

We retrieved the relevant articles of the associations between these two microRNA polymorphisms and susceptibility to CRC for the period up to July 1, 2013. A total of seven articles were identified with 2,143 cases and 2,457 controls for miR-146a rs2910164, 1,594 cases and 2,252 controls for miR-196a2 rs11614913. Odds ratio and 95 % confidence interval were calculated to investigate the strength of the association.

Results

The pooled analysis showed that miR-146a rs2910164 did not reveal any correlation with CRC susceptibility. However, a decreased risk was observed between miR-196a2 rs11614913 and CRC in all genetic models.

Conclusion

Our current meta-analysis demonstrates that miR-196a2 rs11614913 most likely contributes to decreased risk of CRC, whereas miR-146a rs2910164 may not be associated with the susceptibility to CRC.

Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383–8.PubMedCrossRef

Ogino S, Giovannucci E. Commentary: lifestyle factors and colorectal cancer microsatellite instability-molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol. 2012;41:1072–4.PubMedCentralPubMedCrossRef

Bazensky I, Shoobridge-Moran C, Yoder LH. Colorectal cancer: an overview of the epidemiology, risk factors, symptoms, and screening guidelines. Medsurg Nurs. 2007;16:46–51 (quiz 52).PubMed

Benson AB 3rd. Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm. 2007;13:S5–18.PubMed

Azzoni C, Bottarelli L, Campanini N, Di Cola G, Bader G, Mazzeo A, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis. 2007;22:115–26.PubMedCrossRef

Bognar G, Ledniczky G, Istvan G, Ondrejka P. Molecular mechanisms in development of colorectal cancer metastasis. Magy Seb. 2006;59:342–9.PubMed

Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475–88.PubMedCrossRef

Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013;113:6207–33.

Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and function. Thromb Haemost. 2012;107:605–10.PubMedCrossRef

10.

Van Wynsberghe PM, Chan SP, Slack FJ, Pasquinelli AE. Analysis of microRNA expression and function. Methods Cell Biol. 2011;106:219–52.PubMedCrossRef

11.

Mestdagh P, Lefever S, Pattyn F, Ridzon D, Fredlund E, Fieuw A, et al. The microRNA body map: dissecting microRNA function through integrative genomics. Nucleic Acids Res. 2011;39:e136.PubMedCentralPubMedCrossRef

12.

Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2012;33:254–63.PubMedCrossRef

13.

Min KT, Kim JW, Jeon YJ, Jang MJ, Chong SY, Oh D, et al. Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population. Mol Carcinog. 2012;51(Suppl 1):E65–73.PubMedCrossRef

14.

Lv M, Dong W, Li L, Zhang L, Su X, Wang L, et al. Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population. J Cancer Res Clin Oncol. 2013;139:1405–10.PubMedCrossRef

15.

Hezova R, Kovarikova A, Bienertova-Vasku J, Sachlova M, Redova M, Vasku A, et al. Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol. 2012;18:2827–31.PubMedCentralPubMedCrossRef

16.

Ma L, Zhu L, Gu D, Chu H, Tong N, Chen J, et al. A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch Toxicol. 2013;87:825–33.PubMedCrossRef

17.

Zhan JF, Chen LH, Chen ZX, Yuan YW, Xie GZ, Sun AM, et al. A functional variant in microRNA-196a2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch Med Res. 2011;42:144–8.PubMedCrossRef

18.

Chen H, Sun LY, Chen LL, Zheng HQ, Zhang QF. A variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. Intern Med J. 2012;42:e115–9.PubMedCrossRef

19.

Zhu L, Chu H, Gu D, Ma L, Shi D, Zhong D, et al. A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol. 2012;31:350–4.PubMedCrossRef

20.

Mates IN, Jinga V, Csiki IE, Mates D, Dinu D, Constantin A, et al. Single nucleotide polymorphisms in colorectal cancer: associations with tumor site and TNM stage. J Gastrointestin Liver Dis. 2012;21:45–52.PubMed

21.

Ketting RF. microRNA Biogenesis and Function : an overview. Adv Exp Med Biol. 2011;700:1–14.PubMedCrossRef

22.

Pelletier C, Weidhaas J. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn. 2010;10:817–29.PubMedCrossRef

23.

Liu L, An J, Liu J, Wen J, Zhai X, Liu Y, et al. Potentially functional genetic variants in microRNA processing genes and risk of HBV-related hepatocellular carcinoma. Mol Carcinog. 2013;52 Suppl 1:148–54.

24.

Vinci S, Gelmini S, Mancini I, Malentacchi F, Pazzagli M, Beltrami C, et al. Genetic and epigenetic factors in regulation of microRNA in colorectal cancers. Methods. 2013;59:138–46.PubMedCrossRef

25.

Wang J, Wang Q, Liu H, Shao N, Tan B, Zhang G, et al. The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis. 2012;27:779–88.PubMedCrossRef

26.

Wei WJ, Wang YL, Li DS, Wang Y, Wang XF, Zhu YX, et al. Association between the rs2910164 polymorphism in pre-Mir-146a sequence and thyroid carcinogenesis. PLoS One. 2013;8:e56638.PubMedCentralPubMedCrossRef

27.

Orsos Z, Szanyi I, Csejtei A, Gerlinger I, Ember I, Kiss I. Association of pre-miR-146a rs2910164 polymorphism with the risk of head and neck cancer. Anticancer Res. 2013;33:341–6.PubMed

28.

Nahid MA, Satoh M, Chan EK. MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol. 2011;8:388–403.PubMedCentralPubMedCrossRef

29.

Chassin C, Hempel C, Stockinger S, Dupont A, Kubler JF, Wedemeyer J, et al. MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury. EMBO Mol Med. 2012;4:1308–19.PubMedCentralPubMedCrossRef

30.

Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2008;105:7269–74.PubMedCentralPubMedCrossRef

31.

Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29:2126–31.PubMedCrossRef

32.

Yamashita J, Iwakiri T, Fukushima S, Jinnin M, Miyashita A, Hamasaki T, et al. The rs2910164 G>C polymorphism in microRNA-146a is associated with the incidence of malignant melanoma. Melanoma Res. 2013;23:13–20.PubMedCrossRef

33.

Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One. 2012;7:e50966.PubMedCentralPubMedCrossRef

34.

Guo J, Jin M, Zhang M, Chen K. A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS One. 2012;7:e30585.PubMedCentralPubMedCrossRef

35.

Hong YS, Kang HJ, Kwak JY, Park BL, You CH, Kim YM, et al. Association between microRNA-196a2 rs11614913 genotypes and the risk of non-small cell lung cancer in Korean population. J Prev Med Public Health. 2011;44:125–30.PubMedCentralPubMedCrossRef

36.

Li XD, Li ZG, Song XX, Liu CF. A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology. 2011;42:669–73.CrossRef

Title: Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis
Authors: D. Wan
W. Gu
G. Xu
C. Shen
D. Ding
S. Shen
S. Wang
X. Gong
S. He
Q. Zhi
Publication date: 01-09-2014
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 9/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1150-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2014

Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review

Cell origins and significance of IL-17 in malignant pleural effusion

Overview of a chemoresponse assay in ovarian cancer

Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model

Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma

Exclusive radiotherapy for gliomatosis cerebri: long-term follow-up at a single institution

Keynote webinar | Spotlight on antibody–drug conjugates in cancer